Compare Adaptive Biotechnologies Corp (ADPT) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Solaredge Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Solaredge Technologies Inc trades at $52.7 (market cap $3.22B). The key difference: Adaptive Biotechnologies Corp and Solaredge Technologies Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SEDG | |
|---|---|---|
Market Cap | $3.33B | $3.22B |
Sector | Health | Technology |
52-Week High | $22.37 | $78.51 |
52-Week Low | $10.24 | $24.42 |
Enterprise Value | $3.19B | $3.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SolarEdge Technologies (SEDG) trades at $52.94, up 1.07% on the day, with a bullish technical signal from moving averages and recent positive momentum in solar stocks. The company reported Q1 2026 earnings that missed expectations, with a net loss of $405.45 million on $1.18 billion revenue. Despite negative profitability metrics, SEDG has beaten earnings estimates in two of the last three quarters. Recent news highlights sector-wide gains driven by AI data center power demand and analyst optimism.
The outlook remains mixed: strong solar industry tailwinds and operational cash flow improvement offer potential upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Analyst consensus is cautious with a $32.11 price target below current levels, reflecting concerns over profitability and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
